About Oramed Pharmaceuticals Inc.
https://www.oramed.comOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
CEO
Nadav Kidron
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-01-23 | Reverse | 1:12 |
| 2004-06-14 | Forward | 33:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 10
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
BML CAPITAL MANAGEMENT, LLC
Shares:3.17M
Value:$11.53M
MURCHINSON LTD.
Shares:1.75M
Value:$6.38M
BOOTHBAY FUND MANAGEMENT, LLC
Shares:845.39K
Value:$3.08M
Summary
Showing Top 3 of 63
About Oramed Pharmaceuticals Inc.
https://www.oramed.comOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $2.4M ▼ | $48.4M ▲ | 0% | $1.16 ▲ | $59.48M ▲ |
| Q2-2025 | $0 ▼ | $2.49M ▼ | $13.29M ▲ | 0% ▲ | $0.32 ▲ | $13.16M ▲ |
| Q1-2025 | $2M ▲ | $4.51M ▲ | $-7.64M ▲ | -382.1% ▼ | $-0.19 ▲ | $-4.47M ▲ |
| Q4-2024 | $0 | $3.6M ▲ | $-10.19M ▲ | 0% | $-0.26 ▲ | $-9.75M ▼ |
| Q3-2024 | $0 | $3.09M | $-19.62M | 0% | $-0.48 | $-3.04M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $134.69M ▲ | $220.49M ▲ | $18.16M ▲ | $203.28M ▲ |
| Q2-2025 | $97.94M ▼ | $161.68M ▲ | $8.1M ▲ | $154.53M ▲ |
| Q1-2025 | $130.64M ▼ | $147.54M ▼ | $7.64M ▼ | $140.81M ▼ |
| Q4-2024 | $141.93M ▼ | $155.28M ▼ | $9.93M ▲ | $146.26M ▼ |
| Q3-2024 | $142.3M | $165.08M | $9.56M | $156.44M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $48.4M ▲ | $-1.99M ▲ | $38.84M ▲ | $-392.62K ▼ | $36.38M ▲ | $-1.99M ▲ |
| Q2-2025 | $13.29M ▲ | $-3.57M ▼ | $-55M ▼ | $-372.79K ▼ | $-58.72M ▼ | $-3.57M ▼ |
| Q1-2025 | $-7.64M ▲ | $-3.52M ▼ | $23.62M ▲ | $0 ▲ | $20.1M ▲ | $-3.52M ▼ |
| Q4-2024 | $-10.19M ▲ | $-1.94M ▲ | $15.76M ▲ | $-1.39M ▲ | $12.32M ▲ | $-1.95M ▲ |
| Q3-2024 | $-19.62M | $-7.07M | $-33.59M | $-1.5M | $-42.65M | $-7.08M |
CEO
Nadav Kidron
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-01-23 | Reverse | 1:12 |
| 2004-06-14 | Forward | 33:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 10
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
BML CAPITAL MANAGEMENT, LLC
Shares:3.17M
Value:$11.53M
MURCHINSON LTD.
Shares:1.75M
Value:$6.38M
BOOTHBAY FUND MANAGEMENT, LLC
Shares:845.39K
Value:$3.08M
Summary
Showing Top 3 of 63